High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression

PROGRAM DESCRIPTION
Patients with COVID-19 have varied risk for increasing severity of disease, with the chance of progression and mortality being higher in older patients and those with comorbidities. Monoclonal antibody therapies that prevent the need for hospitalization in high-risk outpatients who have COVID-19 have been given Emergency Use Authorization by the FDA. These agents include a cocktail consisting of casirivimab and imdevimab and a cocktail of bamlanivimab and etesevimab.

This activity High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression will provide clinicians who manage outpatients with COVID-19 with a review of the most current management guidelines and information on the mechanism of action, efficacy and safety data, and patient eligibility for the monoclonal antibodies that have received emergency use authorization (EUA) by the FDA to treat outpatients with COVID-19.

AGENDA
Welcome and Introduction
Recommendations for Outpatient Management of COVID-19
Efficacy and Safety of Monoclonal Antibodies for the Outpatient Management of COVID-19
Q&A Session and Activity Roundup

PROGRAM FACULTY AND STEERING COMMITTEE

Peter Chen, MD
Professor of Medicine and Biomedical Sciences Director,
Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

Raymund R. Razonable, MD
Professor of Medicine
Mayo Clinic
Rochester, MN

TARGET AUDIENCE
The intended audience for this educational initiative is primary care clinicians who are responsible for the outpatient management of patients with mild-to-moderate COVID-19.

EDUCATIONAL OBJECTIVES
At the conclusion of this education, participants should be able to:

• Integrate the most recent recommendations when developing management strategies for outpatients with COVID-19
• Assess the mechanism of action and efficacy and safety data for monoclonal antibodies that have FDA Emergency Use Authorization for managing outpatient COVID-19

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

DISCLOSURE INFORMATION
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Program Faculty and Steering Committee
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Peter Chen, MD: Consultant/Independent Contractor: Eli Lilly, Gilead

Raymund Razonable, MD: Grant/Research Support: Gilead, Regeneron, Roche

Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry A. Glauser, MD, MPH: Nothing to disclose

Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD: Nothing to disclose

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

HARDWARE/SOFTWARE REQUIREMENTS
Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Education resources provided in collaboration with

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Click here for the PCME Privacy Policy